Review
Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem®): Differences in characteristics and misuse

https://doi.org/10.1016/j.drugalcdep.2009.04.012Get rights and content

Abstract

There are distinct differences in the accessibility, purity, dosing, and misuse associated with illicit gamma-hydroxybutyrate (GHB) compared to pharmaceutical sodium oxybate. Gamma-hydroxybutyrate sodium and sodium oxybate are the chemical and drug names, respectively, for the pharmaceutical product Xyrem® (sodium oxybate) oral solution. However, the acronym GHB is also used to refer to illicit formulations that are used for non-medical purposes. This review highlights important differences between illicit GHB and sodium oxybate with regard to their relative abuse liability, which includes the likelihood and consequences of abuse. Data are summarized from the scientific literature; from national surveillance systems in the U.S., Europe, and Australia (for illicit GHB); and from clinical trials and post-marketing surveillance with sodium oxybate (Xyrem). In the U.S., the prevalence of illicit GHB use, abuse, intoxication, and overdose has declined from 2000, the year that GHB was scheduled, to the present and is lower than that of most other licit and illicit drugs. Abuse and misuse of the pharmaceutical product, sodium oxybate, has been rare over the 5 years since its introduction to the market, which is likely due in part to the risk management program associated with this product. Differences in the accessibility, purity, dosing, and misuse of illicit GHB and sodium oxybate suggest that risks associated with illicit GHB are greater than those associated with the pharmaceutical product sodium oxybate.

Introduction

Gamma-hydroxybutyric acid is an endogenous compound and putative neurotransmitter that differs from the primary inhibitory neurotransmitter gamma-aminobutyric acid (GABA) by the substitution of a hydroxyl group in place of the amino group of the GABA molecule (Maitre, 1997, Pardi and Black, 2006). Sodium gamma-hydroxybutyrate or sodium 4-hydroxybutyrate (GHB) is the International Union of Pure and Applied Chemistry chemical name for the sodium salt of gamma-hydroxybutyric acid, whereas sodium oxybate is the international drug name for the identical compound (Hillebrand et al., 2008). Sodium oxybate is marketed as Xyrem® in the U.S., Canada, and Europe by Jazz Pharmaceuticals, Valeant Pharmaceuticals International, and UCB, respectively. It is approved for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy in the U.S., for the treatment of narcolepsy with cataplexy in adult patients in Europe, and for the treatment of cataplexy with narcolepsy in Canada. Sodium oxybate is approved in Germany as an anesthetic, Somsanit® (Dr. F. Köhler Chemie), and is approved in Austria and Italy for the treatment of opioid and alcohol withdrawal as Alcover® (Laboratorio Farmaceutico; Hillebrand et al., 2008). Clinical development programs are also under way to study the clinical efficacy and safety of sodium oxybate for the treatment of conditions such as fibromyalgia (Russell et al., 2009) and essential tremor (Frucht et al., 2005). For the purposes of this report, sodium oxybate will be used to refer to the government-approved drug or pharmaceutical product. GHB will be used to refer to endogenous gamma-hydroxybutyric acid and chemical grade gamma-hydroxybutyrate. Illicit GHB will be used to refer to illicitly manufactured gamma-hydroxybutyric acid or gamma-hydroxybutyrate and street drug products that are purported to be GHB and might contain GHB or other compounds of unknown dose and purity.

GHB was legally manufactured and widely available as a nutritional supplement (to induce sleep or increase muscle mass) in the 1980s until reports of abuse as a “club drug” (a drug used in a club or party setting for its euphoric effects; e.g., Sumnall et al., 2008) and “date-rape drug” (a drug used for drug-facilitated sexual assault; e.g., Chin et al., 1992) led to the scheduling of GHB as a controlled substance. As of March 2000, GHB and sodium oxybate were placed in a unique bifurcated Federal schedule in the U.S.: GHB for non-medical use is Schedule I, the most restrictive schedule of the Controlled Substances Act (2008). When used as prescribed for medical purposes (e.g., the treatment of narcolepsy), it is a Schedule III substance.

In March 2001, the Commission on Narcotic Drugs of the United Nations, at the recommendation of the World Health Organization, added GHB to Schedule IV of the 1971 Convention on Psychotropic Substances, with GHB subject to scheduling or control in all Member States of the European Union. Some Member States (e.g., Italy, Latvia, and Sweden) subsequently also placed controls on one or both of the GHB precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD; Hillebrand et al., 2008). In the U.S., GBL is a List I chemical (a chemical that is used in, and important to, the manufacture of a controlled substance) and is subject to regulatory controls; 1,4-BD is neither controlled nor listed at the Federal level (Controlled Substances Act, 2008), but is controlled in some U.S. states under State Law (e.g., Hawaii, Nevada; Hawaii Revised Statute, 2008, Nevada Administrative Code, 2008). Canada lists sodium oxybate/GHB and all salts as Schedule III.

Distinguishing between illicit GHB and licit GHB or sodium oxybate from clinical case reports of abuse and dependence is difficult. Many of the epidemiological studies or case reports that describe the effects of illicit GHB refer to the molecule simply as GHB (e.g., Kim et al., 2008). Without forensic analysis of the substance consumed or of a biological sample from the consumer, extrapolating effects reported after the administration of illicit GHB or a GHB precursor to the effects of chemical grade GHB or sodium oxybate requires several assumptions to be made, such as the illicit formulation contained GHB, the illicit formulation was not contaminated or adulterated by other chemicals, and the effects were not caused by a co-administered drug or chemical.

However, studies examining the effects of GHB are applicable to sodium oxybate. All pharmaceutical products have chemical names (e.g., sodium gamma-hydroxybutyrate), non-proprietary pharmaceutical names (e.g., sodium oxybate), and trade names (e.g., Xyrem). Clinical studies that were conducted with pharmaceutical grade GHB prior to the development of sodium oxybate as a commercial product (e.g., Broughton and Mamelak, 1979, Scharf et al., 1985) use the chemical name GHB and are applicable to the pharmaceutical product. The use of the chemical name in the scientific literature has likely persisted because of the availability and use of chemical grade GHB for non-human studies (e.g., Carter et al., 2003, Goodwin et al., 2005)

It is important, however, to recognize that illicit GHB and sodium oxybate have different risks or liabilities of abuse and using “GHB” to refer to both illicit GHB and sodium oxybate has blurred this distinction in the scientific literature and in the popular press. The purpose of this review is to summarize the differences between the relative abuse liability of sodium oxybate and that of illicit GHB, with a specific focus on the availability and prevalence of non-medical use, and the risks and consequences of misuse and abuse. Relative abuse liability includes both a drug's liability for abuse (likelihood that the drug will be abused) and its liability of abuse (consequences of abuse; Griffiths et al., 2003). Information on sodium oxybate, GHB, and illicit GHB from three types of sources are presented in this review: data from the peer-reviewed scientific literature; data from national surveys of drug use, abuse, and law enforcement activity; and data from Jazz Pharmaceuticals on the rates of abuse, diversion, drug-facilitated sexual assault, and deaths associated with sodium oxybate.

Section snippets

Availability of illicit GHB

After GHB was scheduled in the U.S. in 2000 and became an illegal drug, it continued to be sold as a dietary supplement under a variety of different names, as a GHB alternative, or more covertly, as a solvent not recommended for human consumption (Maxwell and Spence, 2005). Chemistry kits, reagents, and recipes to convert GHB precursors into GHB also became available for purchase over the internet; however, the availability of these kits, reagents, and recipes is thought to have diminished in

Substance Abuse and Substance Dependence with illicit GHB

In cases of intoxication or unintentional overdose, the dose or doses of illicit GHB are often unknown; however, surveys of users of illicit GHB provide some information about the effects of acute illicit GHB intoxication. In surveys of recreational users of illicit GHB in the U.S., U.K., and Australia, individuals reported using GHB for euphoric-, sociable-, and aphrodisiac-like effects (Miotto et al., 2001, Degenhardt et al., 2002, Barker et al., 2007, Sumnall et al., 2008). In some of the

Discussion and conclusions

There are important differences between illicit GHB and the pharmaceutical product sodium oxybate in accessibility, purity, and dosing, as well as in the prevalence and potential consequences of misuse and abuse. Illicit GHB and GHB precursors are more widely available than sodium oxybate, which is manufactured and distributed under strict conditions that allow the prospective monitoring of potential cases of abuse and dependence. Illicit GHB is synthesized and sold in a manner in which the

Role of funding source

Support to prepare an initial draft of this manuscript was provided to Jane Gorsline under a consulting agreement with Jazz Pharmaceuticals. Support for Roland Griffiths’ involvement was provided in part by grant R01 DA03889 from the National Institute on Drug Abuse.

Contributors

Daniel Pardi and Jane Gorsline were involved in the initial literature search and the writing of the first draft. Lawrence Carter and Roland Griffiths reviewed data from the national surveillance systems and Jazz Pharmaceuticals and were involved in the writing of subsequent drafts. All authors contributed to and have approved the final manuscript.

Conflict of interest

Lawrence Carter is a former employee of Jazz Pharmaceuticals and owns company stock. Daniel Pardi is a former employee of Jazz Pharmaceuticals, owns company stock, and has served as a paid consultant for UCB. Jane Gorsline has served as a paid consultant for Jazz Pharmaceuticals, Neurocrine Biosciences, and Somaxon Pharmaceuticals. Roland Griffiths is principal investigator on grants R01 DA03889 and R01 DA03890 from the National Institute on Drug Abuse and is co-investigator on a contract and

Acknowledgements

We thank Grace Wang who provided data from Jazz Pharmaceuticals for analysis, Elizabeth Crane who provided guidance regarding the use of DAWN data, and Susanna Grzeschik, Diane Guinta, and Deborah Waxman for helpful editorial comments. Drs. Wang, Guinta, and Ms. Waxman are current employees of Jazz Pharmaceuticals and own company stock and hold company stock options. Dr. Grzeschik is a former employee of Jazz Pharmaceuticals and owns company stock.

References (104)

  • M.A. LeBeau et al.

    Further evidence of in vitro production of gamma-hydroxybutyrate (GHB) in urine samples

    Forensic Sci. Int.

    (2007)
  • T.L. Litovitz et al.

    2001 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System

    Am. J. Emerg. Med.

    (2002)
  • M. Maitre

    The γ-hydroxybutyrate signaling system in brain: organization and functional implications

    Prog. Neurobiol.

    (1997)
  • K.L. Nicholson et al.

    GHB: a new and novel drug of abuse

    Drug Alcohol Depend.

    (2001)
  • H.R. Sumnall et al.

    Use, function, and subjective experiences of gamma-hydroxybutyrate (GHB)

    Drug Alcohol Depend.

    (2008)
  • W.A. Watson et al.

    2004 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System

    Am. J. Emerg. Med.

    (2005)
  • W.A. Watson et al.

    2003 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System

    Am. J. Emerg. Med.

    (2004)
  • W.A. Watson et al.

    2002 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System

    Am. J. Emerg. Med.

    (2003)
  • S. Abanades et al.

    Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users

    J. Clin. Psychopharmacol.

    (2007)
  • S. Abanades et al.

    Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics

    Ann. N.Y. Acad. Sci.

    (2006)
  • Australian Institute of Health and Welfare, 2008. 2007 National Drug Strategy Household Survey: first results. Drug...
  • J.C. Barker et al.

    Experiences of gamma hydroxybutyrate (GHB) ingestion: a focus group study

    J. Psychoactive Drugs.

    (2007)
  • M.A. Bellis et al.

    The role of an international nightlife resort in the proliferation of recreational drugs

    Addiction

    (2003)
  • L.A. Borgen et al.

    The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients

    J. Clin. Pharmacol.

    (2004)
  • A.C. Bronstein et al.

    2006 Annual Report of the American Association of Poison Control Centers’ National Poison Data System

    Clin. Toxicol.

    (2007)
  • A.C. Bronstein et al.

    2007 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 25th Annual Report

    Clin. Toxicol.

    (2008)
  • R. Broughton et al.

    The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate

    Can. J. Neurol. Sci.

    (1979)
  • D.G. Caldicott et al.

    Fatalities associated with the use of γ-hydroxybutyrate and it analogues in Australasia

    Med. J. Aust.

    (2004)
  • L.P. Carter et al.

    The role of GABAB receptors in the discriminative stimulus effects of γ-hydroxybutyrate in rats: time course and antagonism studies

    J. Pharmacol. Exp. Ther.

    (2003)
  • Carter, L.P., Griffiths, R.R., Mintzer, M.Z., 2007. Psychomotor, subjective, and cognitive effects of GHB and triazolam...
  • L.P. Carter et al.

    Relative abuse liability of GHB in humans: a comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB

    Neuropsychopharmacology

    (2006)
  • L.P. Carter et al.

    Novel gamma-hydroxybutyric acid (GHB) analogs share some, but not all behavioral effects of GHB and GABAB receptor agonists

    J. Pharmacol. Exp. Ther.

    (2005)
  • Centers for Disease Control

    Multistate outbreak of poisonings associated with illicit use of gamma hydroxy butyrate

    JAMA

    (1991)
  • M.Y. Chin et al.

    Acute poisoning from γ-hydroxybutyrate in California

    West. J Med.

    (1992)
  • F.J. Couper et al.

    Suspected GHB overdoses in the emergency department

    J. Anal. Toxicol.

    (2004)
  • L. Degenhardt et al.

    Recent trends in the use of “club drugs”: an Australian review

    Subst. Use Misuse

    (2005)
  • L. Degenhardt et al.

    The prevalence and correlates of gamma-hydroxybutyrate (GHB) overdose among Australian users

    Addiction

    (2003)
  • P.M. Dietze et al.

    Patterns and incidence of gamma-hydroxybutyrate (GHB)-related ambulance attendances in Melbourne

    Victoria Med. J. Aust.

    (2008)
  • J.D. Doherty et al.

    Metabolism of γ-hydroxy-[1-14C] butyrate by rat brain: relationship to the Krebs cycle and metabolic compartmentation of amino acids

    J. Neurochem.

    (1978)
  • P. Dupont et al.

    Near-fatal gamma-butyrolactone intoxication—first report in the UK

    Hum. Exp. Toxicol.

    (2001)
  • M.A. ElSohly et al.

    Prevalence of drugs used in cases of alleged sexual assault

    J. Anal. Toxicol.

    (1999)
  • European Monitoring Centre for Drugs and Drug Addiction, Annual report 2007: the state of the drugs problem in Europe....
  • European Monitoring Centre for Drugs and Drug Addiction, Annual report 2008: the state of the drugs problem in Europe....
  • S.D. Ferrara et al.

    Fatality due to gamma-hydroxybutyric acid (GHB) and heroin intoxication

    J. Forensic Sci.

    (1995)
  • S.J. Frucht et al.

    A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor

    Neurology

    (2005)
  • D.E. Fuller et al.

    The Xyrem risk management program

    Drug Saf.

    (2004)
  • G.P. Galloway et al.

    Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence

    Addiction

    (1997)
  • A. Glasper et al.

    Within-patient variability in clinical presentation of gamma-hydroxybutyrate withdrawal: a case report

    Eur. Addict. Res.

    (2005)
  • A.K. Goodwin et al.

    Involvement of gamma-hydroxybutyrate (GHB) and GABA-B receptors in the acute behavioral effects of GHB in baboons

    Psychopharmacology

    (2005)
  • A.K. Goodwin et al.

    Chronic intragastric administration of gamma-butyrolactone produces physical dependence in baboons

    Psychopharmacology

    (2006)
  • Cited by (0)

    View full text